Welcome to
JIBAN JYOTI PANDA Research Lab
Welcome to JIBAN JYOTI RESEARCH Lab
Glioma is the most common primary malignant brain tumour. Treatment for glioma, require nanotherapeutics to efficiently cross the blood-brain barrier (BBB) and highly enhanced accumulation within tumor regions.
Despite noteworthy research in the discovery and development of neural therapeutics, brain drug delivery still encounters limited success due to meager perviousness of most of the drug molecules through the BBB, a tight layer of endothelial cells that selectively impedes routing of the molecules across itself.
We aimed for the development and evaluation of self-assembled novel peptide nanostructures capable of traversing the blood brain barrier for effective glioblastoma therapy.
Glioma is the most common primary malignant brain tumour. Treatment for glioma, require nanotherapeutics to efficiently cross the blood-brain barrier (BBB) and highly enhanced accumulation within tumor regions.
Despite noteworthy research in the discovery and development of neural therapeutics, brain drug delivery still encounters limited success due to meager perviousness of most of the drug molecules through the BBB, a tight layer of endothelial cells that selectively impedes routing of the molecules across itself.
We aimed for the development and evaluation of self-assembled novel peptide nanostructures capable of traversing the blood brain barrier for effective glioblastoma therapy.
According to WHO, Stroke is one of the topmost causes of deaths worldwide. Stroke is the disorder in which oxygen supply in the brain gets disrupted. There is no effective treatment for stroke available. Up till now only one FDA approved drug is there for the stroke therapy i.e. tPA. This also has many drawbacks i.e. circulation half life less than 5 min, free to distribute throughout the body, induce cerebral hemorrhages etc. There is a need to develop new therapeutic approaches for the treatment of stroke, and the field of nanotechnology provides more promising stroke therapies capable of delivering various neuroprotectants to the brain through the Blood Brain Barrier.
Neural tissue damage is permanent and causes lasting disability in patients. Considering the fact that, nerve tissues are post-mitotic and cannot regenerate by themselves, the treatment options for combating neural damage is challenging. “Neural tissue engineering” holds potential to restore functional capabilities of damaged neural tissues. Porous nanofibrous scaffolds may be useful for nervous tissue formation and differentiation in brain and spinal cord injury. Variation in scaffold properties may affect neuronal differentiation.
Targeted cancer nanotherapeutics offers numerous opportunities for the selective uptake of toxic chemotherapies within tumors and cancer cells. The unique properties of nanoparticles, such as their small size, large surface-to-volume ratios, and the ability to achieve multivalency of targeting ligands on their surface, provide superior advantages for nanoparticle-based drug delivery to a variety of cancers.
